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Abstract.  The role(s) of one family of polypeptide 
growth factors in a developing organ system was exam- 
ined.  Renal anlagen (metanephroi)  were surgically re- 
moved from  13-d-old rat embryos and grown in organ 
culture for up to 6 d.  Over this period of time when 
placed in serum-free defined media, the metanephroi 
increased in size and morphologic complexity. Mes- 
senger RNAs for both insulin-like growth factors (IGFs), 
IGF I and IGF H, were present in the metanephroi. 
Immunoreactive IGF I and IGF H were produced by 
the renal anlagen and released into culture media. 
Levels were relatively constant during the 6 d in cul- 
ture and averaged 3.5  x  lO-gM IGF I and 8.3  x  10-gM 
IGF H in media removed from metanephroi after con- 
tact for 24 h.  IGF binding protein activity was not de- 
tected in culture media.  Growth and development of 
metanephroi in vitro was prevented by the addition of 
anti-IGF I or anti-IGF H antibodies to organ cultures. 
IGF H produced by metanephroi was active in an IGF H 
biological assay system and addition of anti-IGF II re- 
ceptor antibodies to organ cultures prevented growth 
and development, consistent with the action of IGF H 
in metanephroi being mediated via the IGF II receptor. 
The data demonstrate production of both IGF I and 
IGF II by developing rat metanephroi in organ culture. 
Each of these peptides is necessary for growth and de- 
velopment of the renal anlage to take place in vitro. 
Our findings suggest that both IGF I and IGF H are 
produced within the developing metanephros  in vivo 
and promote renal organogenesis. 
M 
OST  fetal tissues contain extractable polypeptide 
growth factors or growth factor activities  and ex- 
press  receptors  and  binding  proteins  for  these 
agents. For this reason, members of one or more polypeptide 
growth  factor  families  are  thought  to  regulate  processes 
of morphogenesis,  differentiation  and growth during  mam- 
malian development (20).  Certain of these agents have been 
implicated as causative of organogenesis  of the metanephric 
kidney (2,7).  A role for insulin-like  growth factors (IGFs) ~ 
in this process is supported by several lines of investigation. 
First, mRNAs for IGFs I and H are present in fetal kidneys, 
and both IGF I and IGF H can be extracted from the organ 
(15-17).  Second, receptors for both IGF I and IGF H are 
present in  fetal renal  tissue, establishing  the potential  for 
IGF-mediated signal transduction  (10, 21). In addition,  IGF 
I is produced in vitro by cells removed from fetal kidneys, 
suggesting that synthesis of at least one of the IGFs can occur 
in the metanephros in vivo (11). Finally, IGF II, stimulates 
growth and promotes segmental  differentiation  of tubular 
segments when added as a growth supplement to explants of 
metanephroi  (3). 
Despite what is known about the presence of growth fac- 
tors and mRNAs and receptors for these agents in developing 
tissues, there is a paucity of information  relating directly the 
1. Abbreviation  used in this paper: IGE insulin-like growth factor. 
growth and development of any one specific organ system to 
endogenously produced growth factors.  To address this is- 
sue, in view of what is known about IGFs and fetal kidney, 
we carried  out studies  to define  the dependence of renal 
organogenesis  on IGFs I and II. We removed metanephroi 
from 13-d-old rat embryos and cultured them in serum-free 
defined media for up to 6 d. We probed for IGF I and IGF 
II mRNAs in the tissues, measured synthesis of IGFs in organ 
culture,  and characterized  growth and development  in the 
absence and presence of anti-IGF I or anti-IGF H antibodies 
or anti-IGF H receptor antibodies. We demonstrate that both 
IGF I and IGF II are synthesized by metanephroi from fetal 
rat and that each is required for growth and development to 
take place in vitro. It is likely that both members of this fam- 
ily  of  polypeptide  growth  factors  are  produced  by  the 
metanephros in vivo and promote renal  organogenesis. 
Materials and Methods 
Removal of Embryos  from Rats, Removal of 
Kidneys from Embryos, Dissection of  Kidneys, and 
Organ Culture of Whole Metanephroi 
Embryos  were  removed  from  anaesthetized  pregnant  female  Sprague 
Dawley rats (Harlan, Indianapolis, IN) on day 13 of the pregnancy. Meta- 
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bryos was confirmed by examination of the shape of the ureteric bud. At 
13 d of development the ureteric bud has differentiated into a metanephric 
duct that ends in a pelvis with two branches (1). 
Cultures of whole metanephroi were carried out on sterile membranes 
(No.  110409; Nuclepore Corp., Pleasanton, CA) of 0.8 t~m thickness and 
13 mm diameter in a medium consisting of equal volumes of Dulbeeco's 
modified Eagles medium and Hams FI2 medium supplemented with 25 mM 
Hepes buffer,  sodium bicarbonate (1.1 mg/ml),  10 nM Na2.SeO3.5H20, 
prostagiandin E1 (10  -H M), iron-saturated transferrin (5 ~g/mi), gentami- 
cin (50 #g/ml), Nystatin (50,000  U/ml), and peniciUin/streptomycin  (50 
U/ml). The following additions were made to cultures when indicated in 
the text: monoclonal anti-human IGF I antibodies, kindly provided through 
the National Institute of Diabetes Digestive and Kidney Diseases (NIDDK) 
National Hormone and Pituitary Program by Dr. Robert Baxter, University 
of Sydney, Sydney, Australia, or an equal volume and protein content of 
mouse IgG3 kappa in clarified ascites fluid (Sigma Chemical Co., St. Louis, 
MO); rabbit anti-human IGF I1 antiserum (Calbiochem-Behting Corp., 
San Diego, CA) or an equal volume and protein content of nonimmune rab- 
bit  serum;  or  affinity-purified  anti-bovine cation-independent mannose 
6-phosphate receptor/IGF II receptor antibodies, kindly  provided by Dr. 
W'flliam Sly, St. Louis University School of Medicine, St. Louis, MO. The 
monoclonal anti-IGF I antibody is an IgG3 (4). Its specificity is such that 
there is little or no competition for binding of nsI-IGF I to antibody by rat 
IGF lI (4). The cross-reactivity  of the anti-IGF 11 antiserum for IGF I is 
0.5%  (Calbiocbem-Behring Corp.). Protein was measured by the method 
of Lowry et al.  (19). 
The dilution of anti-IGF I antibodies added to cultures was 1:4,000. The 
choice of this dilution was based upon the observation that a 1:4,000 dilution 
of a different monoelonal antibody to IGF I maximally inhibited DNA syn- 
thesis in platelet-derived  growth factor-primed BALB/c3T3 cells (27). The 
dilution of anti-IGF H antiserum was also 1:4,000. The quantity of anti-IGF 
H receptor antibodies added to cultures was I ttg/ml. The choice of the latter 
two dilutions was based upon availability of antibodies.  Cultures were car- 
tied out for 1-6 d. Media were removed from cultures every 24 h for mea- 
surements  of peptides  or IGF binding proteins and replaced  with fresh 
media. 
Measurement of  lGF I, IGF II, and IGF Binding 
Protein Contents of Media 
IGF I and IGF II contents of media ware determined using radioimmunoas- 
says. The primary antisera used in radioimmunoassays  were a polyclonal 
rabbit anti-human IGF I antiserum provided through the NIDDK by Drs. 
Louis E. Underwood and Judson J. Van Wyk (University of North Carolina, 
Chapel Hill, NC), and anti-human IGF H antiserum (Calbiochem-Behring 
Corp.). Before measurement of peptides,  media (1 ml vol) were extracted 
with 9 vol of 0.2 M acetic acid containing 0.1 M trimethylamine pH 2.8, to 
separate IGF binding protein activity from IGF I (25). The mixture was al- 
lowed  to  incubate at 4"C  for 2  h,  concentrated, resuspended in acetic 
acid/trimethylamine, and injected into a Cls HPLC gel filtration column 
exactly  as before  (25).  Fractions corresponding to those that contained 
~25I-IGF I (,07,000-8,000 D) were collected,  combined, concentrated, re- 
constituted in a radioimmunoassay  buffer and assayed for IGF I, or IGF II 
radioimmunoactivities  (25). 
IGF binding protein activity was measured in samples reconstituted after 
HPLC using a competitive  charcoal-binding assay exactly as in previous 
studies (25) except both 125I-IGF I and t25I-IGF II ware used to detect IGF 
binding activity. To 75-td samples suspended  in radioimmunoassay  buffer 
(25) were added 125I-IGF  I or I/(,030,000 counts per minute, final concen- 
tration 10 pM). The resulting suspension was mixed, and incubated for 2 h 
at 22°C after which charcoal was added to suspensions.  The suspensions 
were mixed, incubated for 8 rain at 2"C, and subjected to centrifngation. 
Radioactivity  in the supernatant was measured using a gamma counter.  In 
suspensions that contained only buffer, ,02 % of the radioactivity was pres- 
ent in the supematant after centrifugatiun (nonspecific binding). We have 
used this technique to detect IGF binding activity originating in renal col 
lecting duct from adult rats (25). In the present studies, six separate experi- 
ments were performed (three each using nsI-IGF I and 125I-IGF II) that 
used supernatants obtained from three metanephroi on the fourth day of 
culture. 
Detection of  lGF I and IGF H mRNAs 
in Metanephroi 
RNA from single freshly dissected metanephroi was  isolated  using the 
method of Chomczymki and Sacchi (8). The solution used in the isolation 
is available commercially as RNAzol B (CINNA/BIOTECX  Laboratories, 
Friendwoud,  TX). 20 #g of yeast tRNA ware added to metanephmi as ear- 
tier. First strand eDNA was synthesized from the RNA transcripts using 
Moloney routine leukemia virus xeverse transcriptase (M-MLV RT; GIBCO 
BRL, Oaithersburg,  MD) and oligo dT as the primer. The cDNAs for IGF 
I arid IGF H ware amplified using the polymerase chain reaction (PCR) (28) 
using sequence specific oligomers.  The 5' and 3' oligomers used in the am- 
plification  of IGF I eDNA correspond to nncleotides 280-298 of exon 2, 
and 584-568 of exon 5 of the rat gene, respectively (31). The IGF II eDNA 
was amplified with oligunucleotides  corresponding to bases 25-45 of exon 
1, and 148-130 of exon 2 (13). The oligomers chosen for PCR ware located 
across introns in the IGF I and IGF II sequences to ensure that amplified 
products originated from mRNA sequences.  The size of the amplified  re- 
gions was visualized after polyacrylamide gel electrophoresis.  Tris-borate 
(89 raM), 2 mM EDTA, pH 8.3, was used as the running buffer. The identity 
of the PCR products was confirmed by restriction digest analysis. 
Measurement of Phospholipase C Activity 
Pbospbolipase C  activity was  evaluated  by measuring levels  of inusitol 
trisphosphate 0ns-P3) in suspensions of canine renal proximal tubular 
basolateral membranes exactly as described in detail before (23). Activities 
ware measured in membranes incubated with or without 10  -9 M human 
recombinant IGF II (hlGF 11) (Baehem Inc., Torrance, CA) or 10  -9 M IGF 
II originating from metanephroi (mIGF 1I). To obtain sufficient quantities 
of mIGF 1I, HPLC fractions  that contained immunoreactive  IGF II originat- 
ing from 25 metanephroi ware pooled and concentrated as described previ- 
ously (25).  Phospholipase C activities ware measured in the presence and 
absence of 5  mM mannose 6-phosphate. Fractions of incubation media 
alone subjected to HPLC corresponding to fractions that contained mIGF 
II in media removed from metanephroi were used in control experiments 
where indicated (Media; see Table I). 
Processing of Cultured Metanephroi for 
Histological Studies 
Cultured metanephroi and filters were fixed in 10% phosphate-buffered  for- 
malin, pH 7.4 for 30 rain at room temperature,  and then stored in 60% etha- 
nol at 40C until processing could be performed.  Metanephroi ware embed- 
ded in paraffin,  sliced  into 5-/zm sections,  and placed on gelatin-coated 
slides  in preparation for staining with hematoxylin-eosin as before (6). 
Results 
Metanephroi placed in organ culture underwent growth and 
development in vitro such that there were increases in size 
and morphologic complexity. This is illustrated in Fig. 1 that 
shows a metanephros removed from a 13-d-old embryo im- 
mediately  after placement  in organ  culture  (top) and the 
same renal anlage 4 days later (center). Typically, the long 
axis of  the metanephros increased by ~50% over this period 
of time and the surface of the metanephros changed from a 
smooth to a more convoluted appearance.  There was little 
additional change in gross morphology between 4 and 6 d 
in culture (bottom). 
Messenger RNAs for both IGF I and IGF II were present 
in whole metanephroi removed from 13-d-old embryos. The 
sizes of the amplified regions for IGF I (241 bp) and IGF II 
(285 bp) are consistent with amplification of IGF I and IGF 
II mRNA sequences (Fig. 2). The 241-bp amplified region 
for IGF I reflects mRNA that does not contain the 52-base 
insert or any sequence from exon 4 as described by Roberts 
et al.  (22). The identities  of the  amplified  regions  were 
confirmed by restriction enzyme digestions. Within the am- 
plified IGF I region there are two Alu I sites (30). The pre- 
dicted three fragments of 117, 68, and 56 bp were produced 
upon digestion. The IGF II sequence contains a Pvu II site 
(13).  Digestion yielded the predicted fragments of 201 and 
84 bp (data not shown). 
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Shown is a 5 % polyacrylarnide gel stained with ethidium bromide. 
On the left are molecular size markers expressed in base pairs. On 
the right are the sizes of the IGF I (241 bp) and IGF II (285 bp) 
cDNAs amplified using the polymerase chain reaction. The gel is 
representative of three experiments. 
Both immunoreactive IGF I and IGF II were synthesized 
by the renal anlage and released into culture media. This is 
shown in Fig.  3 that illustrates levels of IGFs in media re- 
moved from metanephroi on days 1-6 after initiation of cul- 
ture.  Levels of IGF II in media were approximately twice 
those of IGF I. Levels of each peptide were relatively con- 
stant during 6 d of culture. The concentrations of IGFs I and 
II in culture media averaged 3.5  x  10  -9 and 8.3  x  10-9 M 
respectively over this period of time.  In additional experi- 
ments we determined that the radioimmunoassay we em- 
ployed  for  IGF  I  was  completely  insensitive  to  10  -8  M 
recombinant hIGF II (Bachem Inc.) and that the radioimmu- 
noassay that we used for IGF II was completely insensitive 
to  10  -8  M  hlGF  I  (Amgen  Biologicals,  Thousand  Oaks, 
CA) added to media (data not shown).  This demonstrates 
that cross-reactivity of one or both assays for the other mem- 
ber of the IGF family cannot explain the findings of radioim- 
munoactivity for both peptides in the media. Our observa- 
tions establish that metanephroi synthesize both IGF I and 
IGF II in vitro. In contrast to the presence of IGF I and IGF 
II, IGF binding protein activity was not detectable in super- 
natants of metanephroi (data not shown). 
To determine whether IGF I, IGF II, or both peptides pro- 
duced by the renal anlage plays/play a role in growth and de- 
velopmental processes in vitro, we cultured metanephroi re- 
moved from 13-d-old rat embryos in the serum-free defined 
media  (control)  (C)  or  in  the  presence  of  monoclonal 
anti-IGF  I  antibodies  (alGF  I)  or  anti-IGF  II  antiserum 
(alGF II). Dilutions containing the same amount of protein 
of mouse ascitic fluid (AF) and nonimmune rabbit serum (S) 
were substituted for the IGF I and IGF II antibodies, respec- 
tively, in additional control experiments. After 4 d in culture, 
metanephroi were photographed, then fixed, embedded in 
paraffin and sliced into 5-#m sections. Fig. 4 illustrates the 
appearance of whole metanephroi cultured under control (C, 
S, and AF) and experimental conditions (alGF I, and alGF 
I/). Fig. 5 shows microscopic sections sliced perpendicular 
Figure 1.  Photomicrographs of metanephroi.  (Top) Metanephros 
dissected from a 13-d-old rat embryo (day 0).  (Center) The same 
metanephros after 4 d in organ culture using serum-free defined 
media. (Bottom) The same metanephros after 6 d in organ culture. 
Pictures are representative. 
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Figure 3. Levels of IGF I and IGF II in media removed from de- 
veloping rat metanephroi. The volumes of the media were 1 ml per 
explant. Media were removed after 2,1 h  of contact with meta- 
nephroi. Data are expressed as mean -F SE of seven experiments 
(seven metanephroi). 
to plane of the filter and perpendicular to the axis of the 
original ureteric bud midway between the top and bottom of 
the renal anlage. Cells within control metanephroi grow and 
differentiate such that the renal aniage enlarge and the origi- 
nal two branches of the collecting system undergo extensive 
arborization. Neither the ascites fluid, nor the nonimmune 
serum affected growth and differentiation of metanephroi. In 
contrast, if anti-IGF I or anti-IGF II antibodies were added 
to cultures, growth of the metanephros and development of 
the ductal system were markedly inhibited (Fig. 4  and 5). 
These findings demonstrate a dependence of metanephroi in 
organ culture upon IGF I and IGF II. 
Controversy exists  regarding  whether physiological ac- 
tions of IGF II are mediated via interaction of this peptide 
with the IGF I  receptor or with the IGF II receptor (26). 
Bondy et al. demonstrated early and widespread expression 
of the IGF I receptor gene in rat embryos, in contrast to a 
relatively limited and localized pattern of IGF I gene expres- 
sion. They suggested that their findings were consistent with 
actions of both IGF I and IGF II being mediated via the IGF 
I receptor (5). 
We addressed the question of whether the action of IGF 
II to permit development of metanephroi in vitro is exerted 
through the IGF I receptor or through the IGF II receptor 
by first determining whether IGF II of metanephric origin 
(mIGF II) is biologically active. To this end we measured 
phospholipase C  activity in canine renal proximal tubular 
base-lateral membranes incubated with and without hIGF II 
or mIGF II. As shown in Table I, both hlGF II and mIGF 
II stimulated phospholipase C  activity in the membranes. 
Figure 4. Photomicrographs of  meta- 
nephroi. Shown  are metanephroi cul- 
tured for 4 d in the serum-free chem- 
ically defined media (control, C) or 
in media to which the following  addi- 
tions were made: mouse ascites fluid 
(AF); normal rabbit serum (S); an- 
ti-IGF I antibodies (alGF I); anti- 
IGF II antibodies (alGFI1); or anti- 
IGF  H  receptor  antibodies (alGF 
fIR). The pictures are representative 
of 10 separate experiments. 
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nephroi. Shown are hematoxylin and 
eosin-stained  sections  originating 
from metanephroi cultured for 4 d in 
media described in the legend to Fig. 
5. The pictures are representative of 
10 separate experiments. 
IGF I  does not activate this enzyme in baso-lateral mem- 
branes (23). Therefore the stimulation by mlGF II shown in 
Table I could not have resulted from IGF I of metanephric 
origin that was also present in the mlGF II preparations. Ad- 
ditional evidence that mlGF II is the agent in the prepara- 
tions that stimulates phospholipase C, was provided by deter- 
Table I. Production of Ins-P3 in Basolateral 
Membrane Suspensions 
Addition to 
suspension  Ins-P3 
nmol/mg protein~15  s 
None  0.780 + 0.05 
Media  0.835 5:0.09 
M6P  0.895 + 0.05 
hlGF II  2.10 5:0.25 
hlGF II and M6P  4.64 5:0.44 
mlGF II  2.29 5:0.21 
mlGF II and M6P  5.12 5:0.84 
Shown are results of four experiments. Additions to basolateral membrane sus- 
pensions were  5  mM  mannose 6-phosphate (M6P),  10  -9  M  human recom- 
binant IGF II (hlGF) or 10  -9 M IGF II originating from metanephroi (mlGF 
II). hlGF II >  none, P < 0.01; hlGF II and M6P > hIGF II, P < 0.01; mIGF II 
> media, P< 0.01; mlGF II and M6P > mlGF II, P < 0.05 (Dunnett's multiple 
comparison procedure) (12).  Data are expressed as mean  :t:  SE. 
mining whether marmose 6-phosphate potentiates this effect. 
We have shown that mannose 6-phosphate enhances activation 
of phospholipase C in basolateral membranes by IGF U via 
the  IGF  II/mannose  6-phosphate  receptor (24).  As  illus- 
trated in Table I, mannose 6-phosphate potentiated the activ- 
ity of both hIGF II and mlGF II in basolateral membranes. 
This observation indicates that mIGF II is biologically active 
and capable of signal transduction via the IGF II receptor. 
In other experiments, metanephric anlage were cultured in 
the presence of  anti-human IGF II receptor antibodies (alGF 
IIR).  As shown in Fig. 4  and 5  (lower right),  growth and 
differentiation of metanephroi were inhibited by the antibod- 
ies.  These findings provide strong additional evidence that 
the actions of  IGF II to promote these activities are mediated 
via its own receptor. 
Discussion 
The formation ofmetanephric kidney is initiated by the inter- 
action of the ureteric bud with metanephric blastema (29). 
This event occurs at 12.5 d of embryological development in 
the rat (1). The metanephric blastema differentiates into all 
of the tubular structures of the adult nephron with the excep- 
tion of collecting duct that  arises  from the ureteric bud. 
Differentiation of  metanephric blastema and the ureteric bud 
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when the ureteric bud encounters the metanephric blastema. 
The nature of this event (events) is unknown. 
After induction of the metanephros, the kidney develops 
through  an  orderly  process  of tissue  differentiation.  The 
agents that control and regulate this postinductive process 
are unknown. It is proposed that a number of cell adhesion 
molecules,  components  of  the  extracellular  matrix,  and 
polypeptide  growth  factors  coordinate  the  differentiative 
events  (7).  The  roles  of several  putative  coordinators  of 
differentiation  have been  investigated  using  antibodies  di- 
rected against these agents. Antibodies to the epithelial cell 
adhesion molecule, uvomorulin, do not perturb the develop- 
ment of polarized kidney tubules in embryologic organ cul- 
ture (31). In contrast, postinductive differentiation of meta- 
nephric blastema is prevented by antibodies to the cell surface 
disialoganglioside  Gin,  and establishment of epithelial cell 
polarity during tubule development is inhibited by antibodies 
to the basement membrane glycoprotein, laminin (18). These 
observations  indicate  that  GD3 and  laminin  participate  in 
differentiation and development.  Our present findings pro- 
vide compelling evidence for roles of both members of the 
IGF family as well. 
Growth and development of metanephroi in culture were 
markedly inhibited by anti-IGF I or by anti-IGF II antibod- 
ies. Because of the very low or absent reactivity for IGF H 
of the anti-IGF I mAbs used in our experiments, it is unlikely 
that they act to inhibit metanephric growth and development 
by rendering IGF II inactive.  Therefore,  our data strongly 
suggest a necessary role for IGF I in these processes. Because 
the anti-IGF H antibodies are relatively specific for IGF II, 
and  because  anti-IGF  II  receptor  antibodies  also  inhibit 
growth and development, it is probable that IGF H is required 
for growth and development to occur in addition to IGF I. 
The only sources for either peptide in metanephric cultures 
are the metanephroi themselves. Therefore, our observations 
establish roles for both peptides of metanephric origin in re- 
nal growth and organogenic processes  in vitro.  It is likely 
that these  findings reflect roles of endogenously  produced 
IGFs for metanephrogenesis  in vivo. 
Levels of IGF H mRNA and protein in a number of tissues 
are higher during gestation than are levels of IGF I mRNA 
and peptide and, in rodents, the former decline within a few 
weeks postpartum. In contrast, IGF I exhibits the opposite 
pattern of expression. For this reason, it has been proposed 
that IGF II is the predominant fetal mitogen (20).  Our data 
show that IGF I as well as IGF II is produced in developing 
metanephros.  Assuming that the peptides present in media 
are in equilibrium with peptides within metanephroi, the lev- 
els of both IGF I and IGF II in developing kidneys would be 
sufficiently high so as to result in half-maximal binding to 
IGF  receptors  in  most  cellular  systems  including  kidney 
(14). Therefore, it is likely that each peptide is present within 
the metanephros in concentrations that could regulate meta- 
bolic,  growth, and developmental events. 
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